GT BIOPHARMA, INC. (GTBP) scores 35 out of 100 on boothcheck's 11-model valuation framework. Verdict: Bad. Quantitative score: 36/100. Qualitative score: 70/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.